Moroctocog-alfa (AF-CC)
ApprovedBiologic
PfizerMoroctocog-alfa (AF-CC) is one of 35 biologic programs targeting Hemophilia A. It is currently in Approved.
1
Indications
4
Total Trials
0
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
93 competitors in Hemophilia a
#DrugCompanyPhaseTrials
1Hemlibra
RochePhase 3
Recombinant Human Coagulation FVIII
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
Eptacog Alfa
Novo NordiskPhase 3
Qfitlia
GGenzyme, a Sanofi Company
Phase 3
Valoctocogene Roxaparvovec
BioMarin PharmaceuticalPhase 3
Recombinant Factor VIII
BayerPhase 3
PF-06741086
PfizerPhase 3
Marstacimab
PfizerPhase 3
Rfviia
RochePhase 3
Refacto
PfizerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hemophilia A2 trials
Prophylaxis1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Moroctocog-alfa (AF-CC). EMBL-EBI & Wellcome Sanger Institute.
- [4]